Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/DDR1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/DDR1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DDR1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DDR1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DDR1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DDR1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DDR1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DDR1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00075657 | Oral cavity | OSCC | female pregnancy | 98/7305 | 193/18723 | 5.66e-04 | 3.27e-03 | 98 |
GO:005087819 | Oral cavity | OSCC | regulation of body fluid levels | 179/7305 | 379/18723 | 6.19e-04 | 3.50e-03 | 179 |
GO:00485889 | Oral cavity | OSCC | developmental cell growth | 116/7305 | 234/18723 | 6.20e-04 | 3.50e-03 | 116 |
GO:00605609 | Oral cavity | OSCC | developmental growth involved in morphogenesis | 116/7305 | 234/18723 | 6.20e-04 | 3.50e-03 | 116 |
GO:00181083 | Oral cavity | OSCC | peptidyl-tyrosine phosphorylation | 177/7305 | 375/18723 | 6.86e-04 | 3.83e-03 | 177 |
GO:00226171 | Oral cavity | OSCC | extracellular matrix disassembly | 37/7305 | 63/18723 | 1.18e-03 | 5.99e-03 | 37 |
GO:002261214 | Oral cavity | OSCC | gland morphogenesis | 62/7305 | 118/18723 | 1.91e-03 | 8.94e-03 | 62 |
GO:19901388 | Oral cavity | OSCC | neuron projection extension | 86/7305 | 172/18723 | 2.13e-03 | 9.80e-03 | 86 |
GO:003087910 | Oral cavity | OSCC | mammary gland development | 69/7305 | 137/18723 | 4.43e-03 | 1.79e-02 | 69 |
GO:00447067 | Oral cavity | OSCC | multi-multicellular organism process | 105/7305 | 220/18723 | 5.05e-03 | 1.97e-02 | 105 |
GO:19030531 | Oral cavity | OSCC | regulation of extracellular matrix organization | 28/7305 | 48/18723 | 5.17e-03 | 2.02e-02 | 28 |
GO:00605629 | Oral cavity | OSCC | epithelial tube morphogenesis | 149/7305 | 325/18723 | 6.73e-03 | 2.50e-02 | 149 |
GO:006156410 | Oral cavity | OSCC | axon development | 207/7305 | 467/18723 | 1.01e-02 | 3.51e-02 | 207 |
GO:00075667 | Oral cavity | OSCC | embryo implantation | 29/7305 | 53/18723 | 1.46e-02 | 4.76e-02 | 29 |
GO:0022411110 | Oral cavity | LP | cellular component disassembly | 173/4623 | 443/18723 | 9.97e-12 | 7.44e-10 | 173 |
GO:0048732110 | Oral cavity | LP | gland development | 149/4623 | 436/18723 | 4.51e-06 | 9.17e-05 | 149 |
GO:0042060110 | Oral cavity | LP | wound healing | 139/4623 | 422/18723 | 7.10e-05 | 9.48e-04 | 139 |
GO:001604918 | Oral cavity | LP | cell growth | 155/4623 | 482/18723 | 1.08e-04 | 1.31e-03 | 155 |
GO:000155817 | Oral cavity | LP | regulation of cell growth | 134/4623 | 414/18723 | 2.25e-04 | 2.41e-03 | 134 |
GO:0010810110 | Oral cavity | LP | regulation of cell-substrate adhesion | 72/4623 | 221/18723 | 4.80e-03 | 3.03e-02 | 72 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DDR1 | SNV | Missense_Mutation | | c.1852N>C | p.Glu618Gln | p.E618Q | Q08345 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
DDR1 | SNV | Missense_Mutation | rs527938479 | c.1826N>A | p.Arg609Gln | p.R609Q | Q08345 | protein_coding | tolerated(0.69) | benign(0.019) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
DDR1 | SNV | Missense_Mutation | novel | c.1438G>A | p.Glu480Lys | p.E480K | Q08345 | protein_coding | tolerated(0.82) | benign(0.291) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DDR1 | SNV | Missense_Mutation | rs370113205 | c.1696N>A | p.Val566Ile | p.V566I | Q08345 | protein_coding | tolerated(0.06) | probably_damaging(0.964) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
DDR1 | SNV | Missense_Mutation | novel | c.571C>T | p.Leu191Phe | p.L191F | Q08345 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DDR1 | deletion | Frame_Shift_Del | novel | c.949delN | p.Met318CysfsTer5 | p.M318Cfs*5 | Q08345 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
DDR1 | SNV | Missense_Mutation | rs557271556 | c.586G>A | p.Ala196Thr | p.A196T | Q08345 | protein_coding | tolerated(0.09) | benign(0.192) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DDR1 | SNV | Missense_Mutation | rs370297461 | c.2282G>A | p.Arg761His | p.R761H | Q08345 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DDR1 | SNV | Missense_Mutation | novel | c.2569G>A | p.Glu857Lys | p.E857K | Q08345 | protein_coding | deleterious(0) | possibly_damaging(0.699) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DDR1 | SNV | Missense_Mutation | rs776556090 | c.2648N>T | p.Pro883Leu | p.P883L | Q08345 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A2LV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 381118865 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | US9567304, Compound N-9 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | VAPBGCRAUJRZPO-UHFFFAOYSA-N | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | BDBM50080408 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | US9695118, 4 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | NG7 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 328083456 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 178102314 | IMATINIB | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 252827391 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 363894135 | MERESTINIB | |